Publications: DR Sean Carlson
Roberts C, Peters J, Sazonvos A, Goodman N, Sharip M, Smith R, Bishara M, Bewshea C et al.
(
2025
)
.
Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource
.
Alimentary Pharmacology & Therapeutics
vol.
62
,
(
6
)
630
-
645
.
Mathew L, Carlson S, Savage M, Pardieu C, Sze N, Munro C, Naglik J, Stagg A et al.
(
2024
)
.
P145 Phagocyte responses to gut-derived C. albicans are modified in inflammatory bowel disease
.
Journal of Crohn's and Colitis
vol.
18
,
(
Supplement_1
)
i441
-
i441
.
Carlson SL, Mathew L, Savage M, Kok K, Lindsay JO, Munro CA, McCarthy NE
(
2023
)
.
Mucosal Immunity to Gut Fungi in Health and Inflammatory Bowel Disease
.
Journal of Fungi
vol.
9
,
(
11
)
Chanchlani N, Lin S, Auth MK, Lee CL, Robbins H, Looi S, Murugesan SV, Riley T et al.
(
2022
)
.
Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
.
Alimentary Pharmacology & Therapeutics
vol.
56
,
(
8
)
1250
-
1263
.
Mathew L, Carlson S, Savage M, Pardieu C, O’Brien M, Crawley E, Harrow P, Kaune A-K et al.
.
Bacterial suppression of intestinal fungi via activation of human gut γδ T-cells
.